- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01165333
Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma (CILENT-0902)
Cilengitide (EMD121974) in Combination With Irradiation in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma: Phase I Study
Study Overview
Status
Conditions
Detailed Description
The prognosis of children and young adults with a malignant glioma in the brain stem or a recurrent malignant glioma (in whatever site) is very poor. Over the last few decades, many therapeutic trials have been performed but have failed to significantly improve survival in these patients. There is thus a need to test new drugs in these indications. There is a strong biological rationale for the use of anti-angiogenic drugs in high-grade glioma. Cilengitide (EMD121974; Merck KgaA, Darmstadt, Germany), a cyclic pentapeptide containing the sequence RGD (cyclo-[Arg-Gly-Asp-Dphe-(NmeVal)]) is a selective antagonist of integrins αvβ3 and αvβ5, which are strongly involved in tumour angiogenesis. Positive results with Cilengitide in preclinical models of glioblastoma, its particularly attractive safety profile and its encouraging efficacy in phase I and II studies in adults and children make it a potentially effective molecule for the treatment of malignant glioma in children. Furthermore, its combination with radiotherapy to be appears synergistic, without any apparent increase in toxicity.
In this study, Cilengitide will be evaluated when concurrently administered with radiotherapy as a first-line treatment and then as a maintenance monotherapy in children and young adults with malignant brain stem glioma. The main objective will be to determine the maximum tolerated dose (MTD) of Cilengitide when administered twice weekly as a 60-minute intra-venous infusion.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Hôpital des Enfants, Groupe Hospitalier
-
Lille, France, 59020
- Centre Oscar Lambret
-
Lyon, France, 69373
- Centre Léon Bérard
-
Marseille, France, 13385
- CHU, Hôpital d'Enfants de la Timone
-
Nantes, France, 44093
- Centre Hospitalier Universitaire de Nantes
-
Paris, France, 75231
- Institut Curie
-
Strasbourg, France, 67091
- Hôpitaux Universitaires de Strasbourg
-
Toulouse, France, 33059
- CHU
-
Villejuif, France, 94805
- Institut Gustave-Roussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed diffuse intrinsic pontine glioma
- Metastatic disease allowed
MRI measurable disease according to the WHO criteria and for extension cohort
- Patient is able to undergo functional MRI (diffusion, perfusion, spectro)
- Patient is able to undergo FDG-PET and sestamibi SPECT
- Life expectancy > 8 weeks after the start of study treatment.
- No prior chemotherapy for the present cancer; no treatment for any other cancer during the last 5 years.
- No prior cerebral radiation therapy
- Age > 6 months and < 21 years
- Lansky Play Scale > 50 or ECOG Performance Status < 2; NB: Children and young adults with a worse performance status due to glioma-related motor paresis can be included.
- Absolute neutrophils count > 1.5 x 109/l, Platelets > 100 x 109/l
- Total bilirubin < 1,5 x ULN, AST and ALT< 2,5 x ULN
- Serum creatinine ≤ 1,5 X ULN for age. If serum creatinine > 1,5 ULN, creatinine clearance must be > 70 ml/min/1.73 m² (EDTA radioisotope GFR or 24 hours urines collection)
- Normal coagulation tests : prothrombin rate (prothrombin time = PT), TCA (PTT), fibrinogen
- No current organ toxicity > grade 2 according to the NCICTCAE version 4.0, especially cardiovascular or renal disease (nephrotic syndrome, glomerulopathy, uncontrolled high blood pressure despite adequate treatment). In case of known or possible cardiac disease, a cardiological advice will be required prior to the inclusion in the study
- If anticonvulsants are currently administered, the dosing regimen must be stable within 1 week prior to the first dose of Cilengitide
- If corticosteroids are administered, the dosing regimen must be stable ≥ 5 days prior to the first dose of Cilengitide.
- Effective contraception for patients (male and female) of reproductive potential during their entire participation in the study and during 6 months after the last administration of Cilengitide.
- Negative pregnancy test (serum beta-HCG) within 1 week prior to start of study treatment in females of reproductive potential
- Patient covered by government health insurance
- Written informed consent given by patient and/or parents/ guardians prior to the study participation
Exclusion Criteria:
- Inclusion criteria failure
- History of coagulation disorder associated with bleeding or recurrent thrombotic events.
- Prior anti-angiogenic therapy
- Any other concomitant anti-cancer treatment not foreseen by this protocol.
- Concomitant inclusion in another therapeutic clinical trial; participation in another therapeutic clinical trial during the last 30 days.
- Pregnancy or breast feeding woman
- Uncontrolled intercurrent illness or active infection
- Unable for medical follow-up (geographic, social or mental reasons)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dose escalation
In the first part of the trial, a dose-ranging study in ca.
18-21 patients will be done.
A standard dose escalation strategy will be used including 3 to 6 patients at each dose level, the first cohort of patients being treated at dose level one Interventions : Cilengitide dose escalation ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
|
Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose. The Cilengitide dose (mg/m²/infusion)levels are as follows :
Other Names:
1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle.
The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
A pharmacokinetic assessment for Cilengitide will be carried for all patients.
The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
For every patient 1 blood sample will be taken before study treatment.
These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach.
DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
|
EXPERIMENTAL: Cohort extension
An additional 20 patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations Interventions : Cilengitide ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
|
1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle.
The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
A pharmacokinetic assessment for Cilengitide will be carried for all patients.
The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
For every patient 1 blood sample will be taken before study treatment.
These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach.
DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
Other Names:
Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of the Maximal Tolerated Dose of Cilengitide
Time Frame: After 6 weeks of treatment
|
A DLT is defined below: Hematological toxicity:
Non-hematological toxicity: Any grade 3 or 4 non-hematological toxicity of whatever duration with the exception of (i) nausea/vomiting without appropriate treatment, and (ii)isolated, transient fever occurring outside an episode of neutropenia), with the exclusion of toxicities related to any other well-identified cause. |
After 6 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety profile of the Cilengitide
Time Frame: During all the study
|
toxicities (NCI-CTCAE v4.0)
|
During all the study
|
study of the pharmacoKinetic profile of Cilengitide
Time Frame: Day 1 and 2 of first cycle
|
Blood samples of 2 mL will be collected at each time point : before Cilengitide infusion, at the end of infusion, 30 mn after the end of infusion, 60 mn, 90 mn, 2 hrs, 4 hrs, 6 hrs, 24 hrs after the end of infusion
|
Day 1 and 2 of first cycle
|
estimate efficacy in terms of response according to histopathology
Time Frame: Every 3 cycles
|
WHO criteria
|
Every 3 cycles
|
Progression-free and overall survival
Time Frame: During all the study
|
6-month-PFS overall survival
|
During all the study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pierre LEBLOND, MD, Centre Oscar Lambret
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Brain Stem Neoplasms
- Infratentorial Neoplasms
- Glioma
- Diffuse Intrinsic Pontine Glioma
Other Study ID Numbers
- CILENT-0902
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Intrinsic Pontine Glioma
-
National Cancer Institute (NCI)RecruitingRecurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Refractory Diffuse Intrinsic Pontine...United States, Canada
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Solving Kids' CancerCompletedDiffuse Intrinsic Pontine Glioma (DIPG)United States
-
University of California, San FranciscoTranslational Genomics Research InstituteCompletedDiffuse Intrinsic Pontine Glioma (DIPG)United States
-
University of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS); The Chad-Tough... and other collaboratorsRecruitingDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent WHO Grade III Glioma | WHO Grade III GliomaUnited States, Israel, Australia, Netherlands, Switzerland, New Zealand
-
University of FloridaAccelerate Brain Cancer Cure; Lyla Nsouli FoundationActive, not recruitingBrain Stem Glioma | Diffuse Intrinsic Pontine Glioma (DIPG)United States
-
Burzynski Research InstituteSuspendedDiffuse, Intrinsic Pontine GliomaUnited States
-
Shenzhen Geno-Immune Medical InstituteShenzhen Children's Hospital; Shenzhen Hospital of Southern Medical UniversityUnknownDiffuse Intrinsic Pontine Glioma or GlioblastomaChina
-
Hadassah Medical OrganizationCompletedPediatric Malignant Brain Tumor -Diffuse Intrinsic Pontine GliomaIsrael
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedMalignant Glioma | Recurrent Childhood Ependymoma | Recurrent Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Atypical Teratoid/Rhabdoid Tumor | Refractory Diffuse Intrinsic Pontine Glioma | CNS Embryonal Tumor, Not Otherwise SpecifiedUnited States
-
Cheng-Chia (Fred) WuFocused Ultrasound FoundationActive, not recruitingDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Diffuse Pontine and Thalamic GliomasUnited States
Clinical Trials on Cilengitide dose escalation
-
National Cancer Institute, EgyptRecruitingHead and Neck CancerEgypt
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
Weill Medical College of Cornell UniversityActive, not recruiting
-
Cliniques universitaires Saint-Luc- Université...UnknownHead and Neck CancerBelgium
-
University Hospital OlomoucUniversity Hospital Ostrava; Masaryk Memorial Cancer InstituteRecruitingHypoxia | Head and Neck Cancer | Dose Escalation | FMISOCzechia
-
Royal North Shore HospitalRecruitingPalliative RadiotherapyAustralia
-
Hinova Pharmaceuticals Inc.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Istituto Clinico HumanitasRecruitingNon Small Cell Lung Cancer | Lung MetastasesItaly
-
Emory UniversityCompletedBrain Metastasis | NeoplasmUnited States
-
Hinova Pharmaceuticals Aus Pty LtdCompletedMetastatic Castration-resistant Prostate CancerAustralia